Dama Pharmaceutical LLC

Dama Pharmaceutical LLC is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Dama Pharmaceutical LLC. Despite cannabis being in use by humanity for thousands of years, apart from ancient texts about its medical use, as of 2019, there is very little scientific knowledge about how cannabis in its different forms interacts with the human mind and body. Many doctors are reluctant to advise their patients to use cannabis, even for applications like CBD creams for arthritis, which antidotally is known to be effective, because they can’t refer to scientific studies to support their recommendations. With legalization in various forms around the world, there are now new cannabis products coming on to the market daily making all kinds of health claims. Cannabis in the United States is still a Schedule 1 substance so FDA studies have been limited and except for the trials that brought GW Pharmaceuticals to market, it will be years before the FDA catches up to consumer’s needs to know the affects of what they are putting into their bodies. And more importantly, the methodology used by the FDA is in most cases not appropriate to understand cannabis and its interactions with other substances and life style. Dama App Purpose and Functionality The purpose of the Dama App is to collect millions of cross-sectional data points overtime on cannabis consumption, on how cannabis interreacts with food, alcohol, other medications, exercise, mental health and life style factors, and to conduct multi-variate analysis through existing ikioo artificial intelligence algorithms and AI algos developed by doctors and scientists who commission studies. The data and analysis in aggregate are opensource and available on a decentralized ledger, with the data and specific trial analysis owned by the trial sponsor, be it a doctor or product manufacturer and held on ikioo’s permissioned hyperledger. Trial participants both patients and general consumers are paid and rewarded for participation in studies and are joint owners with the trial sponsors of the data, but not the analysis.